G&E Herbal Biotechnology Co., Ltd.
TTPEX:491127.00
TWD
0.00
(0.00%)
ISIN
TW0004911003
Return %
Stock
S&P 500
1Y
-40.61
14.20
3Y
-37.25
81.12
5Y
15.71
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Quarterly Revenue
TWD
•
in mil. unless spec.Quarterly Earnings Per Share
TWD
•
in mil. unless spec.Quarterly Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Kuo Wha Kuo
- Full Time Employees
- 38
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No.92, Keji 5th Road Tainan TQ Taiwan 709015
- IPO Date
- Apr 28, 2008
- Website
- geherbs.com.tw
- Similar Companies
- Business
- G&E Herbal Biotechnology Co., Ltd. engages in the research, development, manufacture, and commercialization of novel botanical extraction technologies and products. The company produces a diverse range of health-related products including Hepanamin capsules targeting liver-related diseases; botanical healthcare products under the G&E series; botanical anti-aging cosmetics such as facial cleansing essence, botanical extract toner, moisturizing cream, serum, essential oils, and glitter series cosmetics; botanical antila series gels; skin care products; food supplements; and adult products including lubricants. It also offers biotechnological services and is recognized for its proprietary extraction technology and standards-compliant manufacturing processes, including PIC/S GMP-certified facilities. Founded in 2002 and headquartered in Tainan City, Taiwan, G&E Herbal Biotechnology operates multiple state-of-the-art sites within Taiwan. In recent years, the company has advanced its new drug development pipeline, notably progressing SR-T100, with clinical trials reaching Phase I for injection formulations and Phase III for gel formulations. It has expanded its strategic efforts in research and commercialization of botanical new drugs and health supplements, with notable partnerships and collaborations to market its Hepanamin product. In 2025, G&E Herbal Biotechnology received the “Emerging Mid-Sized Enterprise Award” for Top 10 Growth and Top 10 Profitability, reflecting its strong financial performance and operational excellence. The company continues to focus on innovation in botanical medicine as it participates in international industry events like BIO Asia–Taiwan 2025 and the Asia Healthcare & Medical Cosmetology Expo. It emphasizes sustainable practices through adherence to Global Reporting Initiative standards and continues to pursue global market expansion with a growing portfolio of scientifically validated natural compounds and new drug candidates. The company targets healthcare markets globally with a focus on botanical drugs, dietary supplements, dermatological care, and functional cosmetics. It maintains close control over the cultivation of plant materials via contracted farmers in Taiwan and monitors quality rigorously from agricultural production through manufacturing. G&E Herbal Biotechnology is led by CEO and founder Kou-Wha Kuo and maintains a strong commitment to research ethics and innovation to deliver clinically effective botanical pharmaceutical and consumer health products to both domestic and international markets.